Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced its financial results for the quarter ended June 30, 2009. During 2009 Isis has continued to successfully execute its business strategy and as a result reported $669...
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
SAN CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the second
quarter ended June 30, 2009.
Net loss for the quarter ended June 30, 2009 was $32.1 million or $0.35 per share, compared to net loss of $...
Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
ZURICH, July 16 /PRNewswire/ -- An innovative treatment for infections of
the respiratory tract in cystic fibrosis patients has received a second
orphan drug designation in the US only weeks after a first designation was
granted. The recent designation relates to Burkholderia cepacia pathogens...
deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke
REYKJAVIK, Iceland, July 13 /PRNewswire-FirstCall/ -- Scientists at
deCODE genetics (Nasdaq: DCGN ) and colleagues from Europe and the United
States today report the discovery of a common single-letter variant in the
sequence of the human genome (SNP) conferring increased risk of atrial
ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
LEUVEN, Belgium and LUND, Sweden, July 3 /PRNewswire-FirstCall/ --
ThromboGenics NV (Euronext Brussels: THR) and co-development partner
BioInvent International (OMXS: BINV) announce that they have started
recruitment of a second
cohort of patients for their Phase II trial of
TB-402. This follo...
Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
Preliminary top-line results of second
Phase III study show highly significant decreases in pain and fatigue and improved daily function in fibromyalgia patients and confirm results from the first Phase III study
PALO ALTO, Calif., and BRUSSELS, June 24 /PRNewswire-FirstCall/ -- press releas...
Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
SAN DIEGO, June 24 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a second
Phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with...
EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health
VIENNA, Austria, and CUXHAVEN, Germany, June 18 /PRNewswire/ -- EUCODIS
Bioscience, a company developing, manufacturing, and marketing enzymes and
other proteins for the chemical industry, announced today that it has
achieved an important milestone in the development of an undisclosed protein
HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
Multi-Center, Randomized Trial to Test Unique Delivery System Using Living Cells to Enhance Wound Healing Marks Milestone for Fort Worth, Texas-based Specialty Biopharmaceutical Company
FORT WORTH, Texas, June 16 /PRNewswire/ -- HEALTHPOINT, Ltd. today announced that it has enrolled the f...
Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
Both Phase III pivotal trials begin enrollment in May 2009; Reinforces Lilly's commitment to Alzheimer's disease and biotech product research
INDIANAPOLIS, May 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) today announced it will begin enrolling patients this month in two...
Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
Completion of enrollment keeps Company on track to report primary study results in third quarter of this year
ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today that enrollment has been completed in the second
Phase II clinical trial of its trival...
Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
Study shows Clonicel(R) and stimulants combined provide greater improvement in symptoms than stimulants alone
DURHAM, N.C., April 23 /PRNewswire/ -- Addrenex Pharmaceuticals, Inc. today announced positive results from a second
phase 3 trial of Clonicel demonstrating that the combination of Cl...
Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
- Anthim Dramatically Improves Survival in Animals with Clinical Symptoms of Anthrax disease -
PINE BROOK, N.J., April 20 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatenin...
Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
ASHBURN, Va., March 19 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the second
of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R)...
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
- 900-mcg Albuferon (albinterferon alfa-2b) dosed every two weeks met the primary efficacy endpoint of sustained virologic response comparable to peginterferon alfa-2a dosed weekly in patients with genotype 1 chronic hepatitis C -
- Patients receiving 900-mcg Albuferon had comparable rates o...
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
PARIS, March 3 /PRNewswire/ -- Novexel, a speciality pharmaceutical
company focused on the discovery and development of novel antibiotics
designed to overcome the significant global problem of microbial resistance,
announces today that its most advanced injectable antibacterial, which
Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
PALO ALTO, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals,
Inc. (Nasdaq: JAZZ ) today announced completion of enrollment in the second
two Phase III pivotal clinical trials of JZP-6 (sodium oxybate) for the
treatment of fibromyalgia.
"Completion of enrollment in thi...
Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
PRINCETON, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq:
MEDX ) announced today results from a preclinical study for MDX-1401, a
second-generation non-fucosylated version of MDX-060 that targets CD30, a
marker for activated lymphocytes that is present on the malignant cells of
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
CAMBRIDGE, Mass., Nov. 20 /PRNewswire/ -- Radius Health ("Radius") announced today that it has raised an additional $15 million to its second
institutional financing round, increasing total Series C investment to $82.5 million and the total amount raised since the company's inception to $106.5 mil...
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
- Planned 15 Patient Cohort Enrolled in Stage A of Trial Assessing Regimen of Bavituximab in Combination With Carboplatin and Paclitaxel -
TUSTIN, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical
company developing ...
Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound
Pivotal Study to Provide Real-World Dosing Simulation of Lilly's Gamma-Secretase Inhibitor
INDIANAPOLIS, Oct. 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company
(NYSE: LLY ) today announced it will begin enrolling patients in a second
Phase III study of LY450139, a ga...
NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
PARIS, September 15 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext
Paris: COX) today announced successful top-line results from the second
phase 3 study for naproxcinod in 1020 patients with osteoarthritis of the
knee (the 302 study). Both doses of naproxcinod (750 mg and 375 mg bid) met
Cytopia Commences Second Phase II Study in Brain Cancer
MELBOURNE, Australia, Sept. 4 /PRNewswire/ -- Cytopia Limited (ASX:
CYT) today announced that it is commencing enrolment for its Phase Ib/II
study of CYT997, the company's novel vascular-disrupting anticancer agent,
in patients with an aggressive form of brain cancer known as glioblastoma
QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
Pivotal Study Seeks to Enroll 750 Women at More Than 100 Sites in the U.S.
ANN ARBOR, Mich., Sept. 4 /PRNewswire/ -- QuatRx Pharmaceuticals, a
privately-held biopharmaceutical company focused on development and
commercialization of compounds to treat endocrine, metabolic and
Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
- First Phase 3 data, from BLISS-52 trial, expected by mid-2009 - - Data from second
Phase 3 trial, BLISS-76, expected by fall 2009 -
ROCKVILLE, Md., Aug. 27 /PRNewswire-FirstCall/ -- Human Genome
Sciences, Inc. (Nasdaq: HGSI ) today announced it has completed enrollment
and initial dosin...
Cardium Reports on Second Quarter 2008 Highlights and Financial Results
SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- Cardium Therapeutics
(Amex: CXM ) today reported recent highlights and developments, as well as
financial results for its second
quarter ended June 30, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO )
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
Successful End of Phase 2 Meeting with the FDA for the Fabry Program and Initiation of Phase 2 Clinical Trial in Pompe are Highlights for the Quarter
CRANBURY, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Amicus Therapeutics
(Nasdaq: FOLD ), a biopharmaceutical compa...
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
MOUNTAIN VIEW, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported today financial results for
the quarter and six month period ended June 30, 2008 and provided an update
on the Company's progress with its product development candidates. The net
Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
Broad New Patent Granted
CAMBRIDGE, Mass. and CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ --
Genzyme Corp. (Nasdaq: GENZ ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS )
today announced that they have begun a phase 3 study of mipomersen in
patients with heterozygo...
Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
SAN FRANCISCO, July 30 /PRNewswire-FirstCall/ -- Nile Therapeutics,
Inc. (Nasdaq: NLTX ), today announced that Mayo Clinic has initiated a Phase
Ib, double-blind, placebo-controlled clinical study of CD-NP, a novel
chimeric natriuretic peptide, in development for the treatment of acute
CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
- Results from Phase II Melanoma Trial Expected in the Fourth Quarter -
BRANFORD, Conn., July 29 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on
oncology, today reported its financial results for the second
Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
BETHESDA, Md., July 29 /PRNewswire-FirstCall/ -- Micromet, Inc.
(Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary
antibodies for the treatment of cancer, inflammation and autoimmune
diseases, today announced that it will host a conference call and audio
webcast on Thu...
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals,
Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing,
developing and commercializing proprietary product candidates principally
for use in the hospital setting, today announced that it will release its
Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
MOUNTAIN VIEW, Calif., July 24 /PRNewswire-FirstCall/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has initiated
Phase 3 clinical trial with AZ-004 (Staccato(R) loxapine).
AZ-004 is an inhalation product candidate being developed for the treatment
Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
SEATTLE, July 23 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has filed
an Investigational New Drug Application with the FDA for the clinical
testing of a proprietary formulation of ebselen for the prevention of
chemotherapy induced hearing loss or ototoxicity. The oral capsule
Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
Orexigen is the only company with two late-stage product candidates to address a broad spectrum of obesity patients
SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics,
Inc. (Nasdaq: OREX ) announced today that it has begun randomizing patients
in ZB-202, a seco...
Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease
- Dimebon Showed Statistically Significant Benefit Versus Placebo on All Key Efficacy Endpoints in First Pivotal Trial -
SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Medivation, Inc.
(Nasdaq: MDVN ) today announced it has initiated dosing of patients in its
second pivotal Phase ...
Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
International Study to Evaluate Efficacy and Safety in Treating a Leading Cause of Blindness
LEVERKUSEN, Germany, MONTVILLE, New Jersey and TARRYTOWN, New York, May
8 /PRNewswire-FirstCall/ -- Bayer HealthCare AG and Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN ) tod...
TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
SAN DIEGO, May 6 /PRNewswire/ -- TriLink BioTechnologies (TriLink), a
leading provider of custom nucleic acid-based compounds, has been awarded a
Phase II Small Business Innovation Research (SBIR) grant of approximately
$750,000 to continue its investigation of modified dNTPs to improve the
Proof of Concept Study in Second Species Demonstrates Increase in Absorption of Oral B12 Using Emisphere Technology
CEDAR KNOLLS, N.J., April 16 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ) announced today that additional
preclinical in vivo studies using dogs further demonstrate that its
proprietary eligen(R) technology enhances the absorption of oral B12. These
data confirm in a...